For debate: that Australia should continue using the quadrivalent vaccine.
Gerard
G
Wain
D000293:Adolescent; D000328:Adult; D001315:Australia; D002648:Child; D003362:Cost-Benefit Analysis; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008403:Mass Screening / Q000191:economics; D032541:Mass Vaccination / Q000191:economics; D030361:Papillomavirus Infections / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology; D015229:Sexually Transmitted Diseases, Viral / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D014626:Vaginal Smears / Q000191:economics
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18